BioVaxys Technology (TSE:BIOV) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioVaxys Technology Corp. has announced the engagement of Dr. Rajkannan Rajagopalan as an advisor to enhance the development and production of the company’s innovative DPX™ vaccine formulations. Dr. Rajagopalan’s extensive experience in nanoparticle formulation for various diseases brings a wealth of knowledge to the company’s vaccine programs, including a peanut allergy vaccine and ongoing oncology and infectious disease studies. His expertise is expected to bolster BioVaxys’s capabilities in creating a thermostable vaccine platform and assisting in the establishment of a non-GLP clinical supply facility.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
